Traws Pharma Inc. (TRAW)
Traws Pharma Statistics
Share Statistics
Traws Pharma has 5.07M shares outstanding. The number of shares has increased by -80.11% in one year.
| Shares Outstanding | 5.07M |
| Shares Change (YoY) | -80.11% |
| Shares Change (QoQ) | 66.36% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.74M |
| Failed to Deliver (FTD) Shares | 686 |
| FTD / Avg. Volume | 0.89% |
Short Selling Information
The latest short interest is 76.88K, so 1.53% of the outstanding shares have been sold short.
| Short Interest | 76.88K |
| Short % of Shares Out | 1.53% |
| Short % of Float | 2.55% |
| Short Ratio (days to cover) | 1.75 |
Valuation Ratios
The PE ratio is -0.08 and the forward PE ratio is -0.07. Traws Pharma's PEG ratio is 0.
| PE Ratio | -0.08 |
| Forward PE | -0.07 |
| PS Ratio | 61.01 |
| Forward PS | 18.3 |
| PB Ratio | -0.44 |
| P/FCF Ratio | -0.46 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Traws Pharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.16, with a Debt / Equity ratio of 0.
| Current Ratio | 2.16 |
| Quick Ratio | 2.16 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $37.67K |
| Profits Per Employee | $-27.75M |
| Employee Count | 6 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -91.02% in the last 52 weeks. The beta is 1.43, so Traws Pharma's price volatility has been higher than the market average.
| Beta | 1.43 |
| 52-Week Price Change | -91.02% |
| 50-Day Moving Average | 2.45 |
| 200-Day Moving Average | 5.97 |
| Relative Strength Index (RSI) | 28.28 |
| Average Volume (20 Days) | 77.14K |
Income Statement
In the last 12 months, Traws Pharma had revenue of 226K and earned -166.52M in profits. Earnings per share was -35.21.
| Revenue | 226K |
| Gross Profit | 226K |
| Operating Income | -142.37M |
| Net Income | -166.52M |
| EBITDA | -24.9M |
| EBIT | -24.91M |
| Earnings Per Share (EPS) | -35.21 |
Balance Sheet
The company has 21.34M in cash and 0 in debt, giving a net cash position of 21.34M.
| Cash & Cash Equivalents | 21.34M |
| Total Debt | 0 |
| Net Cash | 21.34M |
| Retained Earnings | -649.15M |
| Total Assets | 24.96M |
| Working Capital | 13.42M |
Cash Flow
In the last 12 months, operating cash flow was -29.79M and capital expenditures 0, giving a free cash flow of -29.79M.
| Operating Cash Flow | -29.79M |
| Capital Expenditures | 0 |
| Free Cash Flow | -29.79M |
| FCF Per Share | -19.19 |
Margins
Gross margin is 100%, with operating and profit margins of -62997.35% and -73682.74%.
| Gross Margin | 100% |
| Operating Margin | -62997.35% |
| Pretax Margin | -73682.74% |
| Profit Margin | -73682.74% |
| EBITDA Margin | -11016.81% |
| EBIT Margin | -62997.35% |
| FCF Margin | -13182.3% |
Dividends & Yields
TRAW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for TRAW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Sep 23, 2024. It was a backward split with a ratio of 1:25.
| Last Split Date | Sep 23, 2024 |
| Split Type | backward |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | -38.97 |
| Piotroski F-Score | 4 |